50 results about "Anti asthmatic" patented technology

A dosage form is disclosed for administering a leukatriene-receptor antagonist to a patient over time.

The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, antiallergic and anti-asthmatic activity. The extractof Pseudolysimachion genus plantand the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL- 13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

The invention relates to an antibiotic and anti-asthma finishing liquid, a preparation method thereof and an application thereof on fabrics. The finishing liquid comprises components of: 10 to 30g / L of an anti-mite finishing agent component A, 20 to 40g / L of an anti-mite finishing agent component B, 20 to 60g / L of a dispersion stabilizer, 10 to 60g / L of an emulsifier, 30 to 60g / L of urea, 60 to 120g / L of an acrylic ester adhesive, 40 to 100g / L of a softener NDS, and a solvent of water. The components are mixed and stirred, such that a finished product is obtained. The finishing liquid provided by the invention has effects of broad-spectrum antisepticising and high-efficiency mite preventing. The preparation method is simple and easy to apply. Anti-asthma and antibiotic linens developed with the technology provided by the invention have functions of mite inhibiting and mite dissipating. With the linens, diseases relates to mites such as dust mites, especially asthma, can be prevented. Also, with the linens, bacteria and bacteria multiplying can be inhibited, such that living environments for human can be substantially improved.

A cyclic amine compound represented by the following general formula (1): wherein,R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group;W1 and W2 each independently represent N or CH;X represents O, NR4, CONR4 or NR4CO;R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1,a salt thereof and a hydrate thereof are provided.These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

The invention relates to 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones of formula (I)whereinX is -SO2-, -SO-, -(CH2)p-, -(CH2)p-O-, -(CH2)p-(C=O)-, -(CH2)p-(C=O)-NH-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, -CH=CH-(CH2)p-,Y is -(C=O)-, -(C=O)-NH-, -(C=O)-NH-(CH2)p-, -C=O)-(CH2)p-, -(CH2)p-, -(CH2)p-O-, -(CH2)p-(C=O)-, -(CH2)p-(C=O)-NH-, -(CH2)p-(C=O)-NH-(CH2)p-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, -CH=CH-(CH2)p-,Z is -O-, -O-(CH2)p-, -NH-, -NH-(C=O)-, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-CH2-(C=O)- and -NH-(C=O)-CH2-,P is a cardinal number from 1 to 4,R1, R2 and R3 can be the same or different and are:mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having from 5 to 14 ring members; or mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,in which the carbocycles and the heterocycles can be mono- or polysubstituted by:C1-6-alkyl, -O-C1-6-alkyl, -O-C3-7-cycloalkyl, mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having from 3 to 14 ring members, mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,R1 is also H, provided that when X is CH2, then R1 is not H,R3-Z is also NO2,and their pharmaceutically acceptable salts,but excluding compounds of formula (I) in whichif Z is -NH-(C=O)-, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-(C=O)-CH2 and at the same time R1 is phenyl, monosubstituted or polysubstituted by -COOH, -COOC1-6-alkyl, -(CH2)p-COOH, -(CH2)p-COOC1-6-alkyl -CONHC1-6-alkyl, -CONHC6-14-aryl, -CONHSO2C1-6-alkyl, -CONHSO2C6-4-aryl, 1H-tetrazol-5-yl, then R2 is not phenyl, monosubstituted or polysubstituted by CN, halogen, C1-4-alkyl, C1-4-alkyloxy, CF3; andif R3-Z is NO2, then R1-X is not benzyl or 4-methoxybenzyl, and R2-Y is not benzyl or 2-picolyl at the same time; and to pharmaceutical treatment processes, and processes for making.

The invention relates to novel pyrazole 5-lipoxygenase small molecule inhibitors shown in a general formula (I), enantiomers, diastereoisomers, racemic modifications, mixtures, and pharmaceutically acceptable salts thereof. The invention also relates to a method for preparing the pyrazole compounds. In addition, the pyrazole compounds have better prevention and treatment effect on diseases related to leukotriene produced by an experimental 5-lipoxygenase (5-LOX) metabolic pathway. The biological experimental activity shows that the compounds are effective 5-LOX small molecule inhibitors with novel structures. Therefore, the compounds expect to be developed into novel powerful chemical entities for treating diseases such as inflammation, cancer, asthma and atherosclerosis related to 5-LOX and the leukotriene.

The invention discloses a method for preparing an anti-asthmatic medicament of salmeterol. The method comprises the following steps of: adding paraxylene, parahydroxyphenylacrylic acid, formaldehyde and acid medium into a reactor, heating, cooling, filtering, washing and drying to obtain 3-hydroxymethyl-4-hydroxyl-phenylacrylic acid; adding the 3-hydroxymethyl-4-hydroxyl-phenylacrylic acid into the reactor, then adding oxyful, lipase and ethyl acetate to finally obtain 3-hydroxymethyl-4-hydroxyl-(beta-hydroxy)-phenylpropyl aldehyde, adding the 3-hydroxymethyl-4-hydroxyl-(beta-hydroxy)-phenylpropyl aldehyde and 6-(4-phenylbutoxy)hexylamine into the reactor, heating for reflowing, cooling, filtering, adding sodium borohydride in batches into filtrate, stirring at normal temperature, then evaporating to dryness, extracting, combining organic layers, drying, filtering and evaporating to dryness to obtain a solid, and separating by using the column chromatography to obtain the final product. The invention has novel and short synthetic route, convenient experiment operation, higher yield of the target product and lower production cost.

The invention relates to protein earthworms EP-2, as well as its methods and applications. The disclosed earthworms protein EP-2 is based on fresh Eiseniafoetida as raw materials. The said method includes extracting by water-buffer homogenate, precipitating with precipitant, purifying with weak anion exchange resin to obtain a mixture of proteins, including protein F-I-0 and F-I-1 and fibrinolytic enzyme A component of 30%-40%. The earthworms protein EP-2 has a significant role in anti-asthma, and is a kind of active proteins with high medicinal value.

The present invention provides one kind of health wine with health functions of reducing phlegm, relieving cough and relieving asthma. It is prepared with ten kinds of Chinese medicinal materials, including Indian azalea, Chinese yam, lily, fritillary, licorice, etc in certain weight proportion. The present invention has integral functions of reducing phlegm, relieving cough and relieving asthma, fast acting, no toxic side effect and other advantages.

The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1):wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

The invention relates to an animal protein medicament buccal instant preparation, and particularly discloses an earthworm protein-containing buccal instant preparation and a preparation method thereof. The preparation consists of 75 weight percent of earthworm protein extract and 25 weight percent of composite flavoring agent, wherein the protein content of the earthworm protein extract is more than 50 percent. In addition, the invention also discloses the preparation method and application of the preparation. The preparation has the obvious antiasthmatic effect, and can effectively inhibit asthma reaction caused by antigen attack of eggalbumin sensitized guinea pigs; and the action mechanism of the preparation is possibly related to anti-leukotriene effect through preliminary analysis of isolated trachea smooth muscle.

The invention relates to an anti-asthmatic and anti-inflammatory medicament and a preparation method and application thereof. The anti-asthmatic and anti-inflammatory medicament is made from the following raw materials in parts by weight: 5 to 8 parts of Ardisia crenata, 5 to 7 parts of Bergenia purpurascens, 1 to 3 parts of Tibetan hellebore, 5 to 7 parts of Crepis phoenix, 1 to 3 parts of Anemone rivularis, 2 to 4 parts of Herba Epimedii, 2 to 4 parts of Gentiana rhodantha and 3 to 4 parts of Polygonum cuspidatum. The medicament has the effects of removing heat and toxic substances, moistening the lung, stopping cough, relieving asthma and tonifying the kidney-yang; and has a high effective rate and a stable long-term efficacy.

The invention discloses an application of pyrroloquinoline quinone to medicines resistant to asthma and allergic reaction. Pyrroloquinoline quinone can relieve allergic airway inflammation through antioxidant and anti-inflammatory effects, and is a potential novel medicine for the treating asthma. Pyrroloquinoline quinone has high antioxidant and anti-inflammatory effects. The in-vivo and in-vitrostudies carried out by the invention show that pyrroloquinoline quinone can reduce allergic airway inflammation by improving the immune microenvironment and regulating a JAK-STAT signaling pathway, and research shows that pyrroloquinoline quinone is safe for oral administration, so that pyrroloquinoline quinone is a potential novel medicine for treating asthma. Pyrroloquinoline quinone exists naturally in nature and can be supplemented by diet, the safety is good, the side effects are low, and the accessibility is high. Pyrroloquinoline quinone is a non-glucocorticoid immunomodulator that targets an asthma inflammatory pathway, the mechanism of medicine action is different from that of current medicines for treating asthma, and mutual complementing can be carried out.

The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and / or COPD-prophylactic / therapeutic profile with unexpectedly excellent safety. A compound of the formula (1): wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and ureido; R1 is a group selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, nitro, lower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R2 is hydrogen or lower alkyl; and m is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof, possesses highly excellent PDE IV-specific inhibitory actions and is useful as an anti-asthmatic drug and / or a prophylactic / therapeutic drug for COPD with high safety.

The present invention relates to a composition having anti-inflammation, anti-allergic and anti-asthma effects, comprising the extract of Shuizhi and xantholic acid isolated therefrom. Extracts of twigs and twig acid isolated therefrom showed inhibitory effects on LTC4 release in vitro, as well as on IgE levels and cytokine (IL-4, IL-5, and IL-13) production in OVA-induced asthmatic mice , airway hyperresponsiveness and inhibition of leukocyte infiltration. Therefore, they are useful as therapeutic agents or functional health foods for the treatment and prevention of inflammatory, allergic and asthmatic diseases.

The invention relates to the technical field of medicines, and in particular relates to an application of gerbera piloselloides and a gerbera piloselloides extract in preparation of medicines for preventing and / or treating asthma. Research finds that the gerbera piloselloides and the gerbera piloselloides extract, especially a 60% ethanol extraction part of gerbera piloselloides, can play an anti-asthma role by inhibiting IgE generation in serum and inhibiting the levels of IL-8, IL-5, TNF-alpha and other inflammatory factors, and have obvious anti-asthma activity, which indicates that the 60%ethanol extraction part of gerbera piloselloides after elution and purification with 10% ethanol can be used as an anti-asthma effective active part of gerbera piloselloides. The gerbera piloselloides and the gerbera piloselloides extract can obviously improve asthma symptoms, can improve allergic reaction symptoms; moreover, and relieving the damage degree of lung tissues, and can be used to prepare medicines for preventing or treating asthma. In addition, the gerbera piloselloides is a natural Chinese herbal medicine, is safe and is free of toxic and side effects when being used, and has agood application prospect.

The present invention relates to selectively controlling the function of a helper T cell. In the present invention, a mouse lacking a gene involved in ganglioside biosynthesis (ganglioside GM3 synthetase gene) (SAT-I KO) was produced and analyzed. As a result, the present invention provides, for example, a method for screening a substance which induces selective suppression of the function of a helper T cell in an immune response, including control of production of a sphingoglycolipid in the helper T cell, and moderation or suppression of an excessive immune response caused by the suppression of the function, that is, a substance having an immunosuppression activity, an anti-asthmatic action and / or an anti-allergic action.

The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and / or COPD-prophylactic / therapeutic profile with unexpectedly excellent safety. A compound of the formula (1):wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and ureido; R1 is a group selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, nitro, lower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R2 is hydrogen or lower alkyl; and m is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof, possesses highly excellent PDE IV-specific inhibitory actions and is useful as an anti-asthmatic drug and / or a prophylactic / therapeutic drug for COPD with high safety.

The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cyto-protective agents.

A wearable breathing mask configured inform of an anion mask with a material such as, but not limited to cotton, nylon, polyethene, polypropylene or some other material used to produce textiles or another suitable breathable substrate. This material acts as a substrate displaying distanced anion emitters completely covering the nostril and mouth area to ensure the constant flow of anions but avoid the avoid repulsion or unflattering appearance. The frame comprises a body with construction or openings to isolate the air circulating within the mask, an adjustable head band to fit on the user's face. The anion emitters may be made by including but not limited to materials such as tourmaline, germanium, or other natural or unnatural emitting materials. The advantages of using the various models of the masks includes helpful in solving numerous problems including but not limited to limitation of Antibacterial effect of anions, antiviral effect of anions, Anti-allergic effects of anions and Anti-asthma effects of anions. The assembly is simple, lightweight, adjustable and comfortable to use similar to normal masks. User can easily get used to inhale thru nose and exhale through mouth or vice versa.

The instant invention provides compounds of Formula (I) which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): 1 wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, antiallergic and anti-asthmatic activity. The extractof Pseudolysimachion genus plantand the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL- 13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

The invention discloses a research method for a screening and extracting process of chamomile anti-asthma active ingredients, and relates to the technical field of chamomile processing. The method comprises the following steps: S01, carrying out clustering analysis on chamomile medicinal materials in different batches, and determining a suitable production place of chamomile; S02, determining optimal extraction conditions of a chamomile active part extraction process by taking dicaffeoylquinic acid content, extract yield and hyaluronidase activity as indexes; and S03, taking the two characteristic components of 3, 5-di-O-caffeoylquinic acid and 4, 5-di-O-caffeoylquinic acid as indexes, purifying the two characteristic components, and determining the optimal purification conditions of the purification process of the chamomile active site. Through the systematic analysis method, the anti-asthma active components in the chamomile are systematically extracted and produced, and through an optimal solution of an extraction and purification process of the anti-asthma active components, the extraction efficiency of the anti-asthma active components in the chamomile is improved, and the production efficiency is improved.

The invention relates to an anti-asthma e-liquid and an anti-asthma electronic cigarette. The anti-asthma e-liquid includes 89%-95% of base oil and 5%-11% of anti-asthma liquid by mass percentage; wherein, the base oil includes glycerin and propylene glycol; the anti-asthma liquid adopts the following mass parts The decoction of each proportioning component is obtained: 2.5-3.5 parts of ephedra, 1.5-2.5 parts of cassia twig, 1.5-2.5 parts of almond and 0.5-1.5 parts of licorice. The above-mentioned anti-asthma e-liquid and anti-asthma e-cigarettes are directly atomized by configuring anti-asthma liquid to act on the lungs, which has a one-step anti-asthma effect, and avoids absorption through internal organs such as the gastrointestinal tract and kidneys, reducing the burden on users. Toxic and side effects of internal organs not only obtains the benefits of traditional Chinese medicine, but also avoids the disadvantages of traditional Chinese medicine, which can be described as the best of both worlds.

The present invention provides a novel process for the preparation of alkyl (1-alkylindol-3-ylmethyl)benzoate derivatives which process comprises the steps of: (a) reacting of an alkyl (halomethyl)benzoate with excess of an indole, said indole being unsubstituted at positions 1-, 2- and 3-, under conditions promoting alkylation at the 3-position of the indole to yield a mixture comprising alkyl (indol-3-ylmethyl)benzoate and unreacted starting indole, (b) treating the mixture obtained in step (a) with base to yield a mixture, comprising the salt of (indol-3-ylmethyl)benzoic acid and the unreacted indole, (c) recovering the unreacted indole from the mixture obtained in step (b), and recycling the indole as starting material to step (a), (d) isolating the salt of (indol-3-ylmethyl)benzoic acid and / or acidifying the salt to form (indol-3-ylmethyl)benzoic acid, (e) reacting the (indol-3-ylmethyl)benzoic acid or it's salt with alkylating agent in the presence of base to form the desired alkyl (1-alkylindol-3-ylmethyl)benzoate. The above process affords also the preparation of the anti-asthmatic leukotriene antagonist zafirlukast. In such case, methyl 3-methoxy-4-(1-methyl-5-nitroindol-3-ylmethyl)benzoate [a]is formed in step (e) of the process and this compound is subsequently converted into zafirlukast by known methods.

The invention relates to an anti-asthmatic and anti-inflammatory medicament and a preparation method and application thereof. The anti-asthmatic and anti-inflammatory medicament is made from the following raw materials in parts by weight: 5 to 8 parts of Ardisia crenata, 5 to 7 parts of Bergenia purpurascens, 1 to 3 parts of Tibetan hellebore, 5 to 7 parts of Crepis phoenix, 1 to 3 parts of Anemone rivularis, 2 to 4 parts of Herba Epimedii, 2 to 4 parts of Gentiana rhodantha and 3 to 4 parts of Polygonum cuspidatum. The medicament has the effects of removing heat and toxic substances, moistening the lung, stopping cough, relieving asthma and tonifying the kidney-yang; and has a high effective rate and a stable long-term efficacy.